Search

Your search keyword '"Benhadou F"' showing total 33 results
Start Over Author "Benhadou F" Search Limiters Full Text
33 results on '"Benhadou F"'

1. Skin and Ultraviolet Neoplasia Transplant Risk Assessment Calculator (SUNTRAC): Perspectives from the EUSCAP database in a cohort of kidney transplant recipients

Author

Al Bouzidi, W., primary, Lipski, J., additional, Wunderlich, K., additional, Njimi, H., additional, Diet, G., additional, Catalano, C., additional, Van Meerhaeghe, T., additional, White, J., additional, Benhadou, F., additional, Suppa, M., additional, Le Moine, A., additional, and del Marmol, V., additional

Published
2024
Full Text
View/download PDF

5. Outcome Measures for the Evaluation of Treatment Response in Hidradenitis Suppurativa for Clinical Practice A HiSTORIC Consensus Statement

Author

Mastacouris, N, Tannenbaum, R, Strunk, A, Koptyev, J, Aarts, P, Alhusayen, R, Bechara, FG, Benhadou, F, Bettoli, V, Brassard, A, Brown, D, Choon, SE, Coutts, P, da Silva, DLF, Daveluy, S, Dellavalle, RP, del Marmol, V, Emtestam, L, Gebauer, K, George, R, Giamarellos-Bourboulis, EJ, Goldfarb, N, Hamzavi, I, Hazen, PG, Horváth, B, Hsiao, J, Ingram, JR, Jemec, GBE, Kirby, JS, Lowes, MA, Marzano, AV, Matusiak, L, Naik, HB, Okun, MM, Oon, HH, Orenstein, LAV, Paek, SY, Pascual, JC, Fernandez-Peñas, P, Resnik, BI, Sayed, CJ, Thorlacius, L, van der Zee, HH, van Straalen, KR, Garg, A, Mastacouris, N, Tannenbaum, R, Strunk, A, Koptyev, J, Aarts, P, Alhusayen, R, Bechara, FG, Benhadou, F, Bettoli, V, Brassard, A, Brown, D, Choon, SE, Coutts, P, da Silva, DLF, Daveluy, S, Dellavalle, RP, del Marmol, V, Emtestam, L, Gebauer, K, George, R, Giamarellos-Bourboulis, EJ, Goldfarb, N, Hamzavi, I, Hazen, PG, Horváth, B, Hsiao, J, Ingram, JR, Jemec, GBE, Kirby, JS, Lowes, MA, Marzano, AV, Matusiak, L, Naik, HB, Okun, MM, Oon, HH, Orenstein, LAV, Paek, SY, Pascual, JC, Fernandez-Peñas, P, Resnik, BI, Sayed, CJ, Thorlacius, L, van der Zee, HH, van Straalen, KR, and Garg, A

Abstract

Importance: Although several clinician- and patient-reported outcome measures have been developed for trials in hidradenitis suppurativa (HS), there is currently no consensus on which measures are best suited for use in clinical practice. Identifying validated and feasible measures applicable to the practice setting has the potential to optimize treatment strategies and generate generalizable evidence that may inform treatment guidelines. Objective: To establish consensus on a core set of clinician- and patient-reported outcome measures recommended for use in clinical practice and to establish the appropriate interval within which these measures should be applied. Evidence Review: Clinician- and patient-reported HS measures and studies describing their psychometric properties were identified through literature reviews. Identified measures comprised an item reduction survey and subsequent electronic Delphi (e-Delphi) consensus rounds. In each consensus round, a summary of outcome measure components and scoring methods was provided to participants. Experts were provided with feasibility characteristics of clinician measures to aid selection. Consensus was achieved if at least 67% of respondents agreed with use of a measure in clinical practice. Findings: Among HS experts, response rates for item reduction, e-Delphi round 1, and e-Delphi round 2 surveys were 76.4% (42 of 55), 90.5% (38 of 42), and 92.9% (39 of 42), respectively; among patient research partners (PRPs), response rates were 70.8% (17 of 24), 100% (17 of 17), and 82.4% (14 of 17), respectively. The majority of experts across rounds were practicing dermatologists with 18 to 19 years of clinical experience. In the final e-Delphi round, most PRPs were female (12 [85.7%] vs 2 males [11.8%]) and aged 30 to 49 years. In the final e-Delphi round, HS experts and PRPs agreed with the use of the HS Investigator Global Assessment (28 [71.8%]) and HS Qu

Published
2023

6. Metascoring Hidradenitis suppurativa

Author

Daoud, M., Njimi, H., Benhadou, F., Suppa, M., Daxhelet, M., Karama, J., White, J., Jemec, G. B.E., del Marmol, V., Daoud, M., Njimi, H., Benhadou, F., Suppa, M., Daxhelet, M., Karama, J., White, J., Jemec, G. B.E., and del Marmol, V.

Published
2021

7. European registry for hidradenitis suppurativa:state of play

Author

Daxhelet, M., Daoud, M., Suppa, M., Benhadou, F., Njimi, H., Tzellos, T., Zouboulis, C. C., Jemec, G. B., del Marmol, V., Daxhelet, M., Daoud, M., Suppa, M., Benhadou, F., Njimi, H., Tzellos, T., Zouboulis, C. C., Jemec, G. B., and del Marmol, V.

Published
2021

8. What causes hidradenitis suppurativa ?—15 years after

Author

Zouboulis, C.C. Benhadou, F. Byrd, A.S. Chandran, N.S. Giamarellos-Bourboulis, E.J. Fabbrocini, G. Frew, J.W. Fujita, H. González-López, M.A. Guillem, P. Gulliver, W.P.F. Hamzavi, I. Hayran, Y. Hórvath, B. Hüe, S. Hunger, R.E. Ingram, J.R. Jemec, G.B.E. Ju, Q. Kimball, A.B. Kirby, J.S. Konstantinou, M.P. Lowes, M.A. MacLeod, A.S. Martorell, A. Marzano, A.V. Matusiak, Ł. Nassif, A. Nikiphorou, E. Nikolakis, G. Nogueira da Costa, A. Okun, M.M. Orenstein, L.A.V. Pascual, J.C. Paus, R. Perin, B. Prens, E.P. Röhn, T.A. Szegedi, A. Szepietowski, J.C. Tzellos, T. Wang, B. van der Zee, H.H.

Abstract

The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as “the only inflammatory skin disease than can be healed”. This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future. © 2020 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd

Published
2020

9. What causes hidradenitis suppurativa ?—15 years after

Author

Zouboulis, C.C. (Christos), Benhadou, F. (Farida), Byrd, A.S. (Angel S.), Chandran, N.S. (Nisha), Giamarellos-Bourboulis, E.J. (Evangelos J.), Fabbrocini, G. (Gabriella), Frew, J.W. (John), Fujita, H. (Hideki), González-López, M.A. (Marcos A.), Guillem, P. (Philippe), Gulliver, W.P. (Wayne P.), Hamzavi, I., Hayran, Y. (Yildiz), Horvath, B.H. (Barbara), Hüe, S. (Sophie), Hunger, R.E., Ingram, J.R. (John R.), Jemec, G.B.E. (Gregor), Ju, Q. (Qiang), Kimball, A.B. (Alexa), Kirby, J.S. (Joslyn S.), Konstantinou, M.P. (Maria P.), Lowes, M.A. (Michelle A.), MacLeod, A.S. (Amanda S.), Martorell, A. (Antonio), Marzano, A.V. (Angelo V.), Matusiak, L., Nassif, A. (Aude), Nikiphorou, E. (Elena), Nikolakis, G. (Georgios), Nogueira da Costa, A. (André), Okun, M. (Martin), Orenstein, L.A.V. (Lauren A.V.), Pascual, J.C. (José Carlos), Paus, R. (Ralf), Perin, B. (Benjamin), Prens, E.P. (Errol), Röhn, T.A. (Till A.), Szegedi, A. (Andrea), Szepietowski, J.C. (J.), Tzellos, T. (Thrasyvoulos), Wang, B. (Baoxi), Zee, H.H. (Hessel) van der, Zouboulis, C.C. (Christos), Benhadou, F. (Farida), Byrd, A.S. (Angel S.), Chandran, N.S. (Nisha), Giamarellos-Bourboulis, E.J. (Evangelos J.), Fabbrocini, G. (Gabriella), Frew, J.W. (John), Fujita, H. (Hideki), González-López, M.A. (Marcos A.), Guillem, P. (Philippe), Gulliver, W.P. (Wayne P.), Hamzavi, I., Hayran, Y. (Yildiz), Horvath, B.H. (Barbara), Hüe, S. (Sophie), Hunger, R.E., Ingram, J.R. (John R.), Jemec, G.B.E. (Gregor), Ju, Q. (Qiang), Kimball, A.B. (Alexa), Kirby, J.S. (Joslyn S.), Konstantinou, M.P. (Maria P.), Lowes, M.A. (Michelle A.), MacLeod, A.S. (Amanda S.), Martorell, A. (Antonio), Marzano, A.V. (Angelo V.), Matusiak, L., Nassif, A. (Aude), Nikiphorou, E. (Elena), Nikolakis, G. (Georgios), Nogueira da Costa, A. (André), Okun, M. (Martin), Orenstein, L.A.V. (Lauren A.V.), Pascual, J.C. (José Carlos), Paus, R. (Ralf), Perin, B. (Benjamin), Prens, E.P. (Errol), Röhn, T.A. (Till A.), Szegedi, A. (Andrea), Szepietowski, J.C. (J.), Tzellos, T. (Thrasyvoulos), Wang, B. (Baoxi), and Zee, H.H. (Hessel) van der

Abstract

The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, the

Published
2020
Full Text
View/download PDF

10. What causes hidradenitis suppurativa ?—15 years after

Author

Zouboulis, CC, Benhadou, F, Byrd, AS, Chandran, NS, Giamarellos-Bourboulis, E J, Fabbrocini, G, Frew, JW, Fujita, H, González-López, MA, Guillem, P, Gulliver, WPF, Hamzavi, I, Hayran, Y, Hórvath, B, Hüe, S, Hunger, RE, Ingram, J R, Jemec, G B, Ju, Q, Kimball, AB, Kirby, JS, Konstantinou, MP, Lowes, MA, MacLeod, AS, Martorell, A, Marzano, AV, Matusiak, ?, Nassif, A, Nikiphorou, E, Nikolakis, G, Costa, A, Okun, M M, Orenstein, LAV, Pascual, JC, Paus, R, Perin, B, Prens, Errol, Röhn, TA, Szegedi, A, Szepietowski, JC, Tzellos, T, Wang, B, van der Zee, Hessel, Zouboulis, CC, Benhadou, F, Byrd, AS, Chandran, NS, Giamarellos-Bourboulis, E J, Fabbrocini, G, Frew, JW, Fujita, H, González-López, MA, Guillem, P, Gulliver, WPF, Hamzavi, I, Hayran, Y, Hórvath, B, Hüe, S, Hunger, RE, Ingram, J R, Jemec, G B, Ju, Q, Kimball, AB, Kirby, JS, Konstantinou, MP, Lowes, MA, MacLeod, AS, Martorell, A, Marzano, AV, Matusiak, ?, Nassif, A, Nikiphorou, E, Nikolakis, G, Costa, A, Okun, M M, Orenstein, LAV, Pascual, JC, Paus, R, Perin, B, Prens, Errol, Röhn, TA, Szegedi, A, Szepietowski, JC, Tzellos, T, Wang, B, and van der Zee, Hessel

Published
2020

11. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients

Author

Benhadou, F. Van der Zee, H.H. Pascual, J.C. Rigopoulos, D. Katoulis, A. Liakou, A.I. Daxhelet, M. Romanelli, M. Iannone, M. Kinyó, Á. Nikolakis, G. Zouboulis, C.C. Dessinioti, C. Zisimou, C. Antoniou, C. Alavi, A. Mintoff, D. Aquilina, S. Matusiak, L. Szepietowski, J.C. Sinclair, R. Husein-ElAhmed, H. von Laffert, M. Revuz, J. Danby, B. Puig, L. Theut Riis, P. Jemec, G.B.E. van van Straalen, K. Wigny, K.M.G.J. del Marmol, V. Guillem, P.

Abstract

Background: Hidradenitis suppurativa (HS), also referred to as acne inversa, is a debilitating skin disease characterized by inflammatory nodules, chronic abscesses and tunnels (fistulae and sinuses). The association with pilonidal sinus disease (PSD) is frequently reported but not well documented. Objectives: To determine the prevalence and characteristics of inflammatory skin lesions located in the intergluteal fold (IGF) of patients with HS. Methods: This was an international multicentre retrospective cross-sectional study based on data collection from a large cohort of patients with HS with and without histopathology. Results From a total of 2465 patients with HS included in the study, 661 (27%) reported lesions in the IGF. These patients were significantly more often smokers and had more severe HS. Of the 238 patients with an available clinical diagnosis, intergluteal-HS (IG-HS) was diagnosed in 52 patients (22%) and PSD was diagnosed in 186 patients (78%). IG-HS was associated with the localization of HS in the proximity of the IGF, including the buttocks, genitals and the anus. There was a possibility of misclassification bias in this study as a clinical/image-based diagnosis or histopathology of the IGF lesions was not always available. Conclusions: The high prevalence of PSD suggests a strong link between both entities. Therefore, it may be useful to identify common pathophysiological mechanisms and develop common therapeutic strategies. What's already known about this topic?. The occurrence of pilonidal sinus disease has not been clearly reported among patients with hidradenitis suppurativa/acne inversa. What does this study add?. This is the first study that investigated the prevalence of pilonidal sinus disease among a large cohort of patients and identified the patient characteristics. Risk factors that might help to improve the management of patients were identified. © 2019 British Association of Dermatologists

Published
2019

12. Pilonidal sinus disease:an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients

Author

Benhadou, F., Van der Zee, H. H., Pascual, J. C., Rigopoulos, D., Katoulis, A., Liakou, A. I., Daxhelet, M., Romanelli, M., Iannone, M., Kinyó, Nikolakis, G., Zouboulis, C. C., Dessinioti, C., Zisimou, C., Antoniou, C., Alavi, A., Mintoff, D., Aquilina, S., Matusiak, L., Szepietowski, J. C., Sinclair, R., Husein-ElAhmed, H., von Laffert, M., Revuz, J., Danby, B., Puig, L., Theut Riis, P., Jemec, G. B.E., van van Straalen, K., Wigny, K. M.G.J., del Marmol, V., Guillem, P., Benhadou, F., Van der Zee, H. H., Pascual, J. C., Rigopoulos, D., Katoulis, A., Liakou, A. I., Daxhelet, M., Romanelli, M., Iannone, M., Kinyó, Nikolakis, G., Zouboulis, C. C., Dessinioti, C., Zisimou, C., Antoniou, C., Alavi, A., Mintoff, D., Aquilina, S., Matusiak, L., Szepietowski, J. C., Sinclair, R., Husein-ElAhmed, H., von Laffert, M., Revuz, J., Danby, B., Puig, L., Theut Riis, P., Jemec, G. B.E., van van Straalen, K., Wigny, K. M.G.J., del Marmol, V., and Guillem, P.

Abstract

Background: Hidradenitis suppurativa (HS), also referred to as acne inversa, is a debilitating skin disease characterized by inflammatory nodules, chronic abscesses and tunnels (fistulae and sinuses). The association with pilonidal sinus disease (PSD) is frequently reported but not well documented. Objectives: To determine the prevalence and characteristics of inflammatory skin lesions located in the intergluteal fold (IGF) of patients with HS. Methods: This was an international multicentre retrospective cross-sectional study based on data collection from a large cohort of patients with HS with and without histopathology. Results From a total of 2465 patients with HS included in the study, 661 (27%) reported lesions in the IGF. These patients were significantly more often smokers and had more severe HS. Of the 238 patients with an available clinical diagnosis, intergluteal-HS (IG-HS) was diagnosed in 52 patients (22%) and PSD was diagnosed in 186 patients (78%). IG-HS was associated with the localization of HS in the proximity of the IGF, including the buttocks, genitals and the anus. There was a possibility of misclassification bias in this study as a clinical/image-based diagnosis or histopathology of the IGF lesions was not always available. Conclusions: The high prevalence of PSD suggests a strong link between both entities. Therefore, it may be useful to identify common pathophysiological mechanisms and develop common therapeutic strategies. What's already known about this topic?. The occurrence of pilonidal sinus disease has not been clearly reported among patients with hidradenitis suppurativa/acne inversa. What does this study add?. This is the first study that investigated the prevalence of pilonidal sinus disease among a large cohort of patients and identified the patient characteristics. Risk factors that might help to improve the management of patients were identified.

Published
2019

13. Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients

Author

Benhadou, F, Van der Zee, HH, Pascual, JC, Rigopoulos, D, Katoulis, A, Liakou, AI, Daxhelet, M, Romanelli, M, Iannone, M, Kinyo, A, Nikolakis, G, Zouboulis, CC, Dessinioti, C, Zisimou, C, Antoniou, C, Alavi, A, Mintoff, D, Aquilina, S, Matusiak, L, Szepietowski, JC, Sinclair, R, Husein-ElAhmed, H, von Laffert, M, Revuz, J, Danby, B, Puig, L, Theut Riis, P, Jemec, GBE, van Straalen, K, Wigny, KMGJ, del Marmol, V, Guillem, P, Benhadou, F, Van der Zee, HH, Pascual, JC, Rigopoulos, D, Katoulis, A, Liakou, AI, Daxhelet, M, Romanelli, M, Iannone, M, Kinyo, A, Nikolakis, G, Zouboulis, CC, Dessinioti, C, Zisimou, C, Antoniou, C, Alavi, A, Mintoff, D, Aquilina, S, Matusiak, L, Szepietowski, JC, Sinclair, R, Husein-ElAhmed, H, von Laffert, M, Revuz, J, Danby, B, Puig, L, Theut Riis, P, Jemec, GBE, van Straalen, K, Wigny, KMGJ, del Marmol, V, and Guillem, P

Abstract

BACKGROUND: Hidradenitis suppurativa (HS), also referred to as acne inversa, is a debilitating skin disease characterized by inflammatory nodules, chronic abscesses and tunnels (fistulae and sinuses). The association with pilonidal sinus disease (PSD) is frequently reported but not well documented. OBJECTIVES: To determine the prevalence and characteristics of inflammatory skin lesions located in the intergluteal fold (IGF) of patients with HS. METHODS: This was an international multicentre retrospective cross-sectional study based on data collection from a large cohort of patients with HS with and without histopathology. Results From a total of 2465 patients with HS included in the study, 661 (27%) reported lesions in the IGF. These patients were significantly more often smokers and had more severe HS. Of the 238 patients with an available clinical diagnosis, intergluteal-HS (IG-HS) was diagnosed in 52 patients (22%) and PSD was diagnosed in 186 patients (78%). IG-HS was associated with the localization of HS in the proximity of the IGF, including the buttocks, genitals and the anus. There was a possibility of misclassification bias in this study as a clinical/image-based diagnosis or histopathology of the IGF lesions was not always available. CONCLUSIONS: The high prevalence of PSD suggests a strong link between both entities. Therefore, it may be useful to identify common pathophysiological mechanisms and develop common therapeutic strategies. What's already known about this topic? The occurrence of pilonidal sinus disease has not been clearly reported among patients with hidradenitis suppurativa/acne inversa. What does this study add? This is the first study that investigated the prevalence of pilonidal sinus disease among a large cohort of patients and identified the patient characteristics. Risk factors that might help to improve the management of patients were identified.

Published
2019

14. Low and high body mass index in hidradenitis suppurativa patients—different subtypes?

Author

Theut Riis, P. Saunte, D.M. Benhadou, F. del Marmol, V. Guillem, P. El-Domyati, M. Abdel-Wahab, H. Antoniou, C. Dessinioti, C. Gürer, M.A. Beksaç, B. Szepietowski, J.C. Matusiak, L. Emtestam, L. Lapins, J. Riad, H. Doss, N. Massa, A.F. Hamzavi, I. Nicholson, C. Dolenc-Voljc, M. Kim, K.H. Ohn, J. Zouboulis, C.C. Karagiannidis, I. Mokos, Z.B. Durinec, P. Jemec, G.B.E.

Subjects
nutritional and metabolic diseases
Abstract

Introduction: Overweight is a well-established risk factor for hidradenitis suppurativa (HS). In this cross-sectional study, we compare HS patients with a high body mass index (BMI) with HS patients with a low BMI to investigate differences in disease characteristics. Materials and method: Patients were recruited from 17 dermatological centres from four continents. A total of 246 patients with a BMI below 25 were compared to 205 patients with a BMI of above 35. Results: Patients with a high BMI suffered more severe disease (Hurley, physician global assessment, number of areas affected and patient-reported severity (PRS), P

Published
2018

15. Low and high body mass index in hidradenitis suppurativa patients-different subtypes?

Author

Theut Riis, P, Saunte, D M, Benhadou, F, Del Marmol, V, Guillem, P, El-Domyati, M, Abdel-Wahab, H, Antoniou, C, Dessinioti, C, Gürer, M A, Beksaç, B, Szepietowski, J C, Matusiak, L, Emtestam, L, Lapins, J, Riad, H, Doss, N, Massa, A F, Hamzavi, I, Nicholson, C, Dolenc-Voljc, M, Kim, K H, Ohn, J, Zouboulis, C C, Karagiannidis, I, Mokos, Z B, Durinec, P, Jemec, G B E, Theut Riis, P, Saunte, D M, Benhadou, F, Del Marmol, V, Guillem, P, El-Domyati, M, Abdel-Wahab, H, Antoniou, C, Dessinioti, C, Gürer, M A, Beksaç, B, Szepietowski, J C, Matusiak, L, Emtestam, L, Lapins, J, Riad, H, Doss, N, Massa, A F, Hamzavi, I, Nicholson, C, Dolenc-Voljc, M, Kim, K H, Ohn, J, Zouboulis, C C, Karagiannidis, I, Mokos, Z B, Durinec, P, and Jemec, G B E

Abstract

INTRODUCTION: Overweight is a well-established risk factor for hidradenitis suppurativa (HS). In this cross-sectional study, we compare HS patients with a high body mass index (BMI) with HS patients with a low BMI to investigate differences in disease characteristics.MATERIALS AND METHOD: Patients were recruited from 17 dermatological centres from four continents. A total of 246 patients with a BMI below 25 were compared to 205 patients with a BMI of above 35.RESULTS: Patients with a high BMI suffered more severe disease (Hurley, physician global assessment, number of areas affected and patient-reported severity (PRS), P < 0.001 for all). There was no difference in smoking (P = 0.783) nor in family history (P = 0.088). In both low and high BMI patients, early onset of HS was a predictor of positive family history (P < 0.001, for each). For low BMI patients, an increase in BMI significantly increased PRS (P < 0.001). For patients with a high BMI, number of pack-years significantly increased PRS (P = 0.001). Cluster analysis of eruption patterns was location specific for low BMI patients but severity specific for high BMI patients.DISCUSSION: Patients with a low and high BMI could represent two clinically different subtypes. We suggest a non-linear relationship between BMI and impact of HS. As patients go from a low BMI patient to a high BMI patient (or from high to low), eruption patterns and risk factors may change.

Published
2018

16. Diagnostic delay in hidradenitis suppurativa is a global problem

Author

Saunte, D.M. Boer, J. Stratigos, A. Szepietowski, J.C. Hamzavi, I. Kim, K.H. Zarchi, K. Antoniou, C. Matusiak, L. Lim, H.W. Williams, M. Kwon, H.H. Gürer, M.A. Mammadova, F. Kaminsky, A. Prens, E. Van Der Zee, H.H. Bettoli, V. Zauli, S. Hafner, J. Lauchli, S. French, L.E. Riad, H. El-Domyati, M. Abdel-Wahab, H. Kirby, B. Kelly, G. Calderon, P. Del Marmol, V. Benhadou, F. Revuz, J. Zouboulis, C.C. Karagiannidis, I. Sartorius, K. Hagströmer, L. McMeniman, E. Ong, N. Dolenc-Voljc, M. Mokos, Z.B. Borradori, L. Hunger, R.E. Sladden, C. Scheinfeld, N. Moftah, N. Emtestam, L. Lapins, J. Doss, N. Kurokawa, I. Jemec, G.B.E.

Published
2015

17. Establishment of a European Registry for hidradenitis suppurativa/acne inversa by using an open source software

Author

Daxhelet, M., Suppa, M, Benhadou, F., Djamei, V., Tzellos, T., Ingvarsson, G., Boer, J., Martorell, A., Ingram, J. R., Desai, Neil B., Nassif, A., Revuz, Jean E., Hotz, Christine, Bettoli, V, Deckers, I. E., Jemec, G. B., Prens, Errol, Zouboulis, C C, Del Marmol, V, Daxhelet, M., Suppa, M, Benhadou, F., Djamei, V., Tzellos, T., Ingvarsson, G., Boer, J., Martorell, A., Ingram, J. R., Desai, Neil B., Nassif, A., Revuz, Jean E., Hotz, Christine, Bettoli, V, Deckers, I. E., Jemec, G. B., Prens, Errol, Zouboulis, C C, and Del Marmol, V

Published
2016

18. Diagnostic delay in hidradenitis suppurativa is a global problem

Author

Saunte, D M, Boer, J, Stratigos, A, Szepietowski, J C, Hamzavi, I, Kim, K H, Zarchi, K, Antoniou, C, Matusiak, L, Lim, H W, Williams, M, Kwon, H H, Gürer, M A, Mammadova, F, Kaminsky, A, Prens, E, van der Zee, H H, Bettoli, V, Zauli, S, Hafner, J, Lauchli, S, French, L E, Riad, H, El-Domyati, M, Abdel-Wahab, H, Kirby, B, Kelly, G, Calderon, P, del Marmol, V, Benhadou, F, Revuz, J, Zouboulis, C C, Karagiannidis, I, Sartorius, K, Hagströmer, L, McMeniman, E, Ong, N, Dolenc-Voljc, M, Mokos, Z B, Borradori, L, Hunger, R E, Sladden, C, Scheinfeld, N, Moftah, N, Emtestam, L, Lapins, J, Doss, N, Kurokawa, I, Jemec, G B E, Saunte, D M, Boer, J, Stratigos, A, Szepietowski, J C, Hamzavi, I, Kim, K H, Zarchi, K, Antoniou, C, Matusiak, L, Lim, H W, Williams, M, Kwon, H H, Gürer, M A, Mammadova, F, Kaminsky, A, Prens, E, van der Zee, H H, Bettoli, V, Zauli, S, Hafner, J, Lauchli, S, French, L E, Riad, H, El-Domyati, M, Abdel-Wahab, H, Kirby, B, Kelly, G, Calderon, P, del Marmol, V, Benhadou, F, Revuz, J, Zouboulis, C C, Karagiannidis, I, Sartorius, K, Hagströmer, L, McMeniman, E, Ong, N, Dolenc-Voljc, M, Mokos, Z B, Borradori, L, Hunger, R E, Sladden, C, Scheinfeld, N, Moftah, N, Emtestam, L, Lapins, J, Doss, N, Kurokawa, I, and Jemec, G B E

Published
2015

19. What causes hidradenitis suppurativa ?—15 years after

Author

Wayne Wpf Gulliver, Antonio Martorell, Hessel H. van der Zee, Aude Nassif, Qiang Ju, Yildiz Hayran, Elena Nikiphorou, Łukasz Matusiak, Farida Benhadou, John R. Ingram, Philippe Guillem, Angel As Byrd, Marcos Ma González-López, Gabriella Fabbrocini, Christos C. Zouboulis, Ralf Paus, Benjamin Perin, Iltefat H. Hamzavi, Nisha Ns Chandran, Joslyn S. Kirby, Evangelos J. Giamarellos-Bourboulis, Angelo V. Marzano, John Jw Frew, Alexa Ab Kimball, Andre Nogueira da Costa, Gregor B.E. Jemec, Martin M. Okun, Hideki Fujita, Maria Mp Konstantinou, Jacek C Szepietowski, Thrasyvoulos Tzellos, Lauren Lav Orenstein, Michelle Ma Lowes, Till Ta Röhn, Andrea Szegedi, Baoxi Wang, José C. Pascual, Robert Re Hunger, Errol P. Prens, Georgios Nikolakis, Amanda S. MacLeod, Barbara Horváth, Sophie Hue, Universidad de Cantabria, Dermatology, Zouboulis, C. C., Benhadou, F., Byrd, A. S., Chandran, N. S., Giamarellos-Bourboulis, E. J., Fabbrocini, G., Frew, J. W., Fujita, H., Gonzalez-Lopez, M. A., Guillem, P., Gulliver, W. P. F., Hamzavi, I., Hayran, Y., Horvath, B., Hue, S., Hunger, R. E., Ingram, J. R., Jemec, G. B. E., Ju, Q., Kimball, A. B., Kirby, J. S., Konstantinou, M. P., Lowes, M. A., Macleod, A. S., Martorell, A., Marzano, A. V., Matusiak, L., Nassif, A., Nikiphorou, E., Nikolakis, G., Nogueira da Costa, A., Okun, M. M., Orenstein, L. A. V., Pascual, J. C., Paus, R., Perin, B., Prens, E. P., Rohn, T. A., Szegedi, A., Szepietowski, J. C., Tzellos, T., Wang, B., and van der Zee, H. H.

Subjects
0301 basic medicine, T-Lymphocytes, Autoimmunity, Biochemistry, 030207 dermatology & venereal diseases, 0302 clinical medicine, Risk Factors, Hidradenitis suppurativa, 610 Medicine & health, B-Lymphocytes, INSULIN-RESISTANCE, hair follicle, pathogenesis, Smoking, Bacterial Infections, Sciences bio-médicales et agricoles, Experimental research, Phenotype, NCSTN MUTATIONS, PYODERMA-GANGRENOSUM, Cholinergic system, Cytokines, ALOPECIA-AREATA, ELEVATED LEVELS, CHOLINERGIC SYSTEM, medicine.medical_specialty, Genotype, Pain, Complement C5a, Dermatology, 03 medical and health sciences, ACNE INVERSA, medicine, BRONCHIAL EPITHELIAL-CELLS, Humans, Molecular Biology, business.industry, Pruritus, Inflammatory skin disease, AUTOINFLAMMATORY SYNDROME, hidradenitis suppurativa, The Renaissance, medicine.disease, inflammatory skin disease, inflammatory skin diseases, 030104 developmental biology, Mutation, acne inversa, Transcriptome, business, SKIN
Abstract

The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30-April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote "Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy." (Kurzen et al. What causes hidradenitis suppurativa? Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the desired renaissance of solid basic HS research is progressing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as "the only inflammatory skin disease than can be healed". This anniversary article of 43 research-performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future., info:eu-repo/semantics/published

Published
2020
Full Text
View/download PDF

20. Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review.

Author

Mendes-Bastos P, Benhadou F, Venturini M, Molina-Levya A, Thomas N, Alarcon I, and Bechara FG

Abstract

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease with a profound disease burden. In recent years, the advent of biologic therapies has improved the treatment landscape for patients with moderate to severe HS. In this new therapeutic era, the role of the general practitioner (GP) in HS treatment is becoming more important than ever. This review discusses how to recognize and diagnose HS by detailing common symptoms. HS can also present with multiple comorbidities. The GP's role in screening for and treating these important comorbidities is pivotal. This review highlights the HS treatment landscape, with a specific focus on what the GP can recommend. The three approved biologics for treating HS include adalimumab, secukinumab and bimekizumab; the benefits and concerns of biologics in everyday clinical practice are detailed. In summary, this review serves as a HS management guide for GPs, with a particular focus on the biologic treatment landscape., Competing Interests: PM-B has received honoraria for acting as a consultant and/or as a speaker for Regeneron, Sanofi Genzyme, AbbVie, Pfizer, Janssen-Cilag, Leo Pharma, Novartis, Eli Lilly, Teva, L’Oreal, Pierre Fabre, Cantabria Labs, Organon, Viatris, Evelo Biosciences, and CS Labs. PM-B is/has been a principal investigator in clinical trials supported by AbbVie, Amgen, Biogen, Janssen, Novartis, Pfizer, and Sanofi. FaB has received honoraria for consultancy/or as speaker for Pfizer, Novartis, Janssen, AbbVie, UCB Pharma, Leo Pharma, and Almirall. MV has served as an advisory board member and/or consultant and has received fees/speaker’s honoraria and/or has participated in clinical trials for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. AM-L has received consultancy/speaker’s honoraria and/or travel grants and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Eli Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB Pharma. NT and IA are employees and stockholders at Novartis Pharma AG, Switzerland. FGB has received honoraria for participation in advisory boards, in clinical trials, and/or as a speaker from AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Acelyrin, Beiersdorf, Boehringer Ingelheim Pharma GmbH & Co. KG, Celltrion, Incyte Corporation, JanssenCilag GmbH, Merck, Mölnlycke, MoonLake, Novartis Pharma GmbH,Sanofi, Sitala, UCB Pharma and Dr. Wolff. The authors declare that this study received funding from Novartis Pharma AG. The funder had the following involvement in the study: medical writing support and facilitated discussions which culminated in the conception of this narrative review. The funder had no role in the review design or decision to publish., (Copyright © 2024 Mendes-Bastos, Benhadou, Venturini, Molina-Levya, Thomas, Alarcon and Bechara.)

Published
2024
Full Text
View/download PDF

21. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.

Author

Daoud M, Suppa M, Benhadou F, Daxhelet M, Njimi H, White J, Jemec G, and Del Marmol V

Abstract

Introduction: Partly due to its clinical heterogeneity, hidradenitis suppurativa (HS) is difficult to score accurately; illustrated by the large number of disease scores. In 2016, a systematic review by Ingram et al. reported the use of about thirty scores, and since then, this number has increased further. Our aim is twofold: to provide a succinct but detailed narrative review of the scores used to date, and to compare these scores with each other for individual patients., Materials and Methods: The review of the literature was done among articles in English and French, on Google, Google scholar, Pubmed, ScienceDirect and Cochrane. To illustrate the differences between scores, data from some Belgian patients included in the European Registry for HS were selected. A first series of patients compares the severity of the following scores: Hurley, Hurley Staging refined, three versions of Sartorius score (2003, 2007, 2009), Hidradenitis Suppurativa Physician Global Assessment (HS-PGA), International Hidradenitis Suppurativa Severity Scoring System (IHS4), Severity Assessment of Hidradenitis Suppurativa (SAHS), Hidradenitis Suppurativa Severity Index (HSSI), Acne Inversa Severity Index (AISI), the Static Metascore, and one score that is not specific to HS: Dermatology Life Quality Index (DLQI). A second set of patients illustrates how some scores change over time and with treatment: Hurley, Hurley Staging refined, Sartorius 2003, Sartorius 2007, HS-PGA, IHS4, SAHS, AISI, Hidradenitis Suppurativa Clinical Response (HiSCR), the very new iHS4-55, the Dynamic Metascore, and DLQI., Results: Nineteen scores are detailed in this overview. We illustrate that for some patients, the scores do not predictably and consistently correlate with each other, either in an evaluation of the severity at a time-point t, or in the evaluation of the response to a treatment. Some patients in this cohort may be considered responders according to some scores, but non-responders according to others. The clinical heterogeneity of the disease, represented by its many phenotypes, seems partly to explain this difference., Conclusion: These examples illustrate how the choice of a score can lead to different interpretations of the response to a treatment, or even potentially change the results of a randomized clinical trial., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Daoud, Suppa, Benhadou, Daxhelet, Njimi, White, Jemec and del Marmol.)

Published
2023
Full Text
View/download PDF

23. Case Report: Comorbid Hyper-IgD Syndrome and Hidradenitis Suppurativa - A New Syndromic Form of HS? A Report of Two Cases.

Author

Guillem P, Mintoff D, Kabbani M, Cogan E, Vlaeminck-Guillem V, Duquesne A, and Benhadou F

Subjects
Comorbidity, Humans, Inflammation complications, Skin, Syndrome, Hidradenitis Suppurativa complications, Mevalonate Kinase Deficiency complications, Mevalonate Kinase Deficiency diagnosis
Abstract

Hidradenitis Suppurativa (HS) is a chronic suppurative disease of the pilosebaceous unit. The current model of HS pathophysiology describes the condition as the product of hyperkeratinisation and inflammation at the hair follicular unit. Environmental factors (such as smoking and obesity), gender, genetic predisposition, and skin dysbiosis are considered the main pathogenic drivers of the disease. Autoinflammatory syndromes associated with HS are rare but may help to highlight the potential roles of autoinflammation and dysregulated innate immune system in HS. Therefore, it is of major relevance to increase the awareness about these diseases in order to improve the understanding of the disease and to optimize the management of the patients. Herein, we report for the first time, to our knowledge, two clinical cases of Hyper-IgD syndrome-associated HS. Hyper-IgD is an autoinflammatory syndrome caused by a mevalonate kinase deficiency (MKD), a key kinase in the sterol and isoprenoid production pathway. We describe the potentially shared pathophysiological mechanisms underpinning comorbid MKD-HS and propose therapeutic options for the management of these patients., Competing Interests: PG received honoraria from AbbVie and Novartis as a consultant and provided lectures for AbbVie, Brothier, Cicaplus, Coloplast, Inresa and Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Guillem, Mintoff, Kabbani, Cogan, Vlaeminck-Guillem, Duquesne and Benhadou.)

Published
2022
Full Text
View/download PDF

24. Unilateral Nevoid Telangiectasia in a Healthy Man.

Author

Küçük K, Bourlond F, Votquenne N, and Benhadou F

Abstract

We report the case of a healthy 26-year-old man presenting telangiectatic macules on the left thorax and arm since childhood. The main diagnostic hypothesis were unilateral nevoid telangiectasia (UNT), hereditary benign telangiectasia, atrial myxoma, segmental serpiginous angioma, circumscribed neviform angiokeratoma, and nevus vascularis mixtus. The diagnosis retained was UNT characterized by congenital or acquired telangiectasia distributed asymmetrically along the upper extremities, or the third or fourth cervical dermatomes. The congenital form is extremely rare, predominant in men, and persists in adulthood. The acquired form is most frequent, affects preferentially women, usually appears at puberty or during pregnancy and tends to disappear. Estrogen excess triggers the formation of telangiectasia. UNT is rarely associated with liver or thyroid disorder. Pulsed-dye lasers and normalization of estrogen are proposed as therapeutic options. We report a rare diagnosis of UNT in a young man with no other underlying condition. We would like to highlight that in the presence of unilateral telangiectasia, a complete clinical examination must be performed to rule out signs of hyperestrogenism in man, ocular or neurological abnormalities, a blood test to exclude pregnancy, hepatic and thyroid dysfunctions, and ultrasonography in case of suspicion of atrial myxoma., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2021 by S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

25. Tuberculosis Risk Stratification of Psoriatic Patients Before Anti-TNF-α Treatment.

Author

Benhadou F, Dirix V, Domont F, Willaert F, Van Praet A, Locht C, Mascart F, and Corbière V

Subjects
Adult, Female, Humans, Incidence, Latent Tuberculosis epidemiology, Male, Middle Aged, Risk Assessment, Tumor Necrosis Factor Inhibitors therapeutic use, Interferon-gamma Release Tests methods, Latent Tuberculosis diagnosis, Psoriasis drug therapy, Tuberculin Test methods
Abstract

Psoriasis is a skin inflammatory condition for which significant progress has been made in its management by the use of targeted biological drugs. Detection of latent M. tuberculosis infection (LTBI) is mandatory before starting biotherapy that is associated with reactivation risk. Together with evaluation of TB risk factors and chest radiographs, tuberculin skin tests (TST) and/or blood interferon-γ-release assays (IGRA), like the QuantiFERON (QFT), are usually performed to diagnose M. tuberculosis infection. Using this approach, 14/49 psoriatic patients prospectively included in this study were identified as LTBI (14 TST + , induration size ≥ 10mm, 8 QFT + ), and 7/14 received prophylactic anti-TB treatment, the other 7 reporting past-treatment. As the specificity and sensitivity of these tests were challenged, we evaluated the added value of an IGRA in response to a mycobacterial antigen associated with latency, the heparin-binding haemagglutinin (HBHA). All but one TST + patient had a positive HBHA-IGRA, indicating higher sensitivity than the QFT. The HBHA-IGRA was also positive for 12/35 TST - QFT - patients. Measurement for 15 psoriatic patients (12 with HBHA-IGRA + ) of 8 chemokines in addition to IFN-γ revealed a broad array of HBHA-induced chemokines for TST + QFT - and TST - QFT - patients, compared to a more restricted pattern for TST + QFT + patients. This allowed us to define subgroups within psoriatic patients characterized by different immune responses to M. tuberculosis antigens that may be associated to different risk levels of reactivation of the infection. This approach may help in prioritizing patients who should receive prophylactic anti-TB treatment before starting biotherapies in order to reduce their number., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Benhadou, Dirix, Domont, Willaert, Van Praet, Locht, Mascart and Corbière.)

Published
2021
Full Text
View/download PDF

26. Effectiveness and tolerability of guselkumab in patients with psoriasis: A longitudinal Belgian retrospective multicenter study.

Author

Ghislain PD, Failla V, Lambert J, Soenen R, Grine L, Tannous J, Guiot F, Willaert F, Fierens H, Vandaele M, Boonen H, Saerens J, Meuleman V, Stockman A, Belpaire A, Swimberghe S, Temmerman L, Dekeyser S, Lambert JM, de Schaetzen V, de la Brassinne M, and Benhadou F

Abstract

Competing Interests: Dr Ghislain provides consultancy to, receives fees as a speaker and/or investigator from, or receives grants from 10.13039/100004319Pfizer, MSD, 10.13039/100006483AbbVie, Janssen, Serono, Leo, 10.13039/100004336Novartis, 10.13039/100011110UCB, 10.13039/100002429Amgen, Eli 10.13039/100004312Lilly, 10.13039/501100009754Galderma, BMS, Meda, Maruho, Flen, Menarini, Almirall, PellePharm, and Viatris. Dr Jo Lambert has been an advisor/speaker for Janssen, Leo Pharma, AbbVie, and Novartis. Dr Grine has been a speaker for AbbVie. Dr Willaert has been an advisor/speaker for Janssen, Leo Pharma, AbbVie, Celgene, and Novartis. Dr Fierens has been an advisor for Janssen, Leo Pharma, and Novartis. Dr Vandaele has been an advisor/speaker for Janssen, Leo Pharma, and Novartis. Dr Boonen has been an advisor/speaker for Celgene, Leo Pharma, Janssen-Cilag, Lily, Novartis, UCB, Almirall, AbbVie, Fresenius Kabi, Mylan, and Sanofi. Dr de Schaetzen has been an advisor/speaker for AbbVie, Novartis, and Leo Pharma. Dr de la Brassinne has received lecture and/or consultation fees and/or travel reimbursement from AbbVie, Almirall, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, and Pfizer. Drs Failla, Soenen, Tannous, Guiot, Saerens, Meuleman, Stockman, Belpaire, Swimberghe, Temmerman, Dekeyser, Jean-Michel Lambert, and Benhadou have no conflicts of interest to declare.

Published
2021
Full Text
View/download PDF

27. Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa.

Author

Duchatelet S, Miskinyte S, Delage M, Ungeheuer MN, Lam T, Benhadou F, Del Marmol V, Vossen ARJV, Prens EP, Cogrel O, Beylot-Barry M, Girard C, Vidil J, Join-Lambert O, Parisot M, Nitschké P, Hanein S, Fraitag S, Van der Zee HH, Bessis D, Damiani G, Altomare A, Liao YH, Nikolakis G, Zouboulis CC, Nassif A, and Hovnanian A

Subjects
Adolescent, Adult, Aged, Amyloid Precursor Protein Secretases physiology, Cohort Studies, Female, Humans, Male, Membrane Glycoproteins genetics, Membrane Proteins genetics, Middle Aged, Presenilin-1 genetics, Young Adult, Amyloid Precursor Protein Secretases genetics, Hidradenitis Suppurativa genetics, Mutation
Published
2020
Full Text
View/download PDF

28. Epidermal autonomous VEGFA/Flt1/Nrp1 functions mediate psoriasis-like disease.

Author

Benhadou F, Glitzner E, Brisebarre A, Swedlund B, Song Y, Dubois C, Rozzi M, Paulissen C, Del Marmol V, Sibilia M, and Blanpain C

Subjects
Animals, Antibodies, Blocking pharmacology, Chromatin Assembly and Disassembly drug effects, Epidermal Cells drug effects, Epidermal Cells pathology, Keratinocytes drug effects, Keratinocytes metabolism, Mice, Knockout, Phenotype, Proto-Oncogene Proteins c-fos metabolism, Psoriasis genetics, Signal Transduction drug effects, Transcription Factors metabolism, Transcription, Genetic drug effects, Epidermal Cells metabolism, Neuropilin-1 metabolism, Psoriasis metabolism, Psoriasis pathology, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor Receptor-1 metabolism
Abstract

Psoriasis is a common chronic skin disorder characterized by keratinocyte hyperproliferation with altered differentiation accompanied by inflammation and increased angiogenesis. It remains unclear whether the first events that initiate psoriasis development occur in keratinocytes or inflammatory cells. Here, using different psoriasis mouse models, we showed that conditional deletion of Flt1 or Nrp1 in epidermal cells inhibited psoriasis mediated by Vegfa overexpression or c-Jun/JunB deletion. Administration of anti-Nrp1 antibody reverted the psoriasis phenotype. Using transcriptional and chromatin profiling of epidermal cells following Vegfa overexpression together with Flt1 or Nrp1 deletion, we identified the gene regulatory network regulated by Vegfa / Nrp1 / Flt1 during psoriasis development and uncovered a key role of Fosl1 in regulating the chromatin remodeling mediated by Vegfa overexpression in keratinocytes. In conclusion, our study identifies an epidermal autonomous function of Vegfa/Nrp1/Flt1 that mediates psoriatic-like disease and demonstrates the clinical relevance of blocking Vegfa/Nrp1/Flt1 axis in psoriasis., (Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)

Published
2020
Full Text
View/download PDF

30. Low Back Pain in Hidradenitis Suppurativa: A Diagnosis Not to Miss!

Author

Schnebert B, Del Marmol V, and Benhadou F

Abstract

We report the case of a patient suffering from hidradenitis suppurativa since puberty and complaining of chronic low back pain associated to altered sensitivity and muscular weakness in the right leg. A diagnosis of lumbosciatica was confirmed. Symptoms were not relieved after the use of nonsteroidal anti-inflammatory drugs and analgesics. A surgical decompression was then indicated but heavily debated. Indeed, extended inflammatory and fibrotic hidradenitis suppurativa lesions were located regarding the skin area eligible for the proposed surgery. A combined therapy with clindamycine/rifampicin was started and the surgery was postponed. A complete remission of the articular symptoms was observed 1 month after the start of the antibiotherapy and the inflammatory skin lesions were greatly improved. With the presentation of this clinical case, we would like to discuss the spectrum of rheumatic disorders associated to hidradenitis suppurativa that needs to be correctly diagnosed and taken into consideration in the therapeutic management of the patient.

Published
2018
Full Text
View/download PDF

31. Psoriasis and Microbiota: A Systematic Review.

Author

Benhadou F, Mintoff D, Schnebert B, and Thio HB

Abstract

Background: Recent advances have highlighted the crucial role of microbiota in the pathophysiology of chronic inflammatory diseases as well as its impact on the efficacy of therapeutic agents. Psoriasis is a chronic, multifactorial inflammatory skin disorder, which has a microbiota distinct from healthy, unaffected skin., Aim: Through an extensive review of the literature, we aim to discuss the skin and gut microbiota and redefine their role in the pathogenesis of psoriasis., Conclusions: Unfortunately, the direct link between the skin microbiota and the pathogenesis of psoriasis remains to be clearly established. Apart from improving the course of psoriasis, selective modulation of the microbiota may increase the efficacy of medical treatments as well as attenuate their side effects.

Published
2018
Full Text
View/download PDF

32. Acute Erythroderma in a Patient Receiving TNF-α-Blocking Therapy for Hidradenitis Suppurativa.

Author

Benhadou F, Hellgren G, Willaert F, and Del Marmol V

Abstract

Tumor necrosis factor-α (TNF-α) normally binds to TNF-α receptors, leading to the inflammatory response of autoimmune diseases. Adalimumab is a TNF-inhibiting, anti-inflammatory, biological medication which binds to TNF-α, thus reducing this inflammatory response. The use of TNF-α-inhibiting medication, such as adalimumab, being the first FDA-approved treatment for hidradenitis suppurativa, has drastically changed the management of dermatological diseases. One rarely reported manifestation that occurs as a side effect associated with the use of TNF-α-blocking agents is erythroderma. This study, for the first time, reports the case of a patient suffering from hidradenitis suppurativa with concomitant psoriasis, who developed a severe and acute erythrodermic rash after the start of adalimumab therapy.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results